191 related articles for article (PubMed ID: 1446056)
21. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin.
Wick MR; Lillemoe TJ; Copland GT; Swanson PE; Manivel JC; Kiang DT
Hum Pathol; 1989 Mar; 20(3):281-7. PubMed ID: 2542151
[TBL] [Abstract][Full Text] [Related]
22. Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma.
Dilley WG; Leight GS; Silva JS; Ammirata S; Haagensen DE; Wells SA
J Natl Cancer Inst; 1983 Jan; 70(1):69-74. PubMed ID: 6571924
[TBL] [Abstract][Full Text] [Related]
23. Presence of alpha-lactalbumin, epidermal growth factor, epithelial membrane antigen, and gross cystic disease fluid protein (15,000 daltons) in breast cyst fluid.
Collette J; Hendrick JC; Jaspar JM; Franchimont P
Cancer Res; 1986 Jul; 46(7):3728-33. PubMed ID: 3486713
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.
Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Drago J; Rohner T; Haagensen D; Glode M; Santner SJ
Anticancer Res; 1984; 4(3):141-4. PubMed ID: 6380398
[TBL] [Abstract][Full Text] [Related]
25. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.
Mazoujian G; Pinkus GS; Davis S; Haagensen DE
Am J Pathol; 1983 Feb; 110(2):105-12. PubMed ID: 6130702
[TBL] [Abstract][Full Text] [Related]
27. Stimulatory effect of oestradiol-17 beta and tamoxifen on gross cystic disease fluid protein 15,000 production and mRNA levels in T47D human breast cancer cells.
Dejardin L; Gol-Winkler R; Collette J; Delvenne C; Carlisi I; Haagensen DE; Franchimont P
J Mol Endocrinol; 1991 Oct; 7(2):105-12. PubMed ID: 1930624
[TBL] [Abstract][Full Text] [Related]
28. Gross cystic disease fluid protein (GCDFP-15) in the breast: past and present.
Sapino A; Cassoni P; Bussolati G
J Biol Regul Homeost Agents; 2000; 14(4):259-62. PubMed ID: 11215813
[No Abstract] [Full Text] [Related]
29. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Hackenberg R; Schulz KD
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):113-7. PubMed ID: 8603031
[TBL] [Abstract][Full Text] [Related]
30. Breast gross cystic disease protein 15 in human breast cancer in culture.
Miller WR; Shivas AA; Franchimont P; Haagensen DE
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):223-8. PubMed ID: 3356211
[TBL] [Abstract][Full Text] [Related]
31. Kappa casein, lactalbumin and GCDFP 70 localization in human breast carcinomas: an immunohistochemical study using the avidin-biotin-peroxidase complex method.
Charpin C; Martin PM; Lachard A; Jacquemier J; Lavaut MN; Andonian C; Pourreau-Schneider N; Toga M
Med Oncol Tumor Pharmacother; 1985; 2(2):103-12. PubMed ID: 2997552
[TBL] [Abstract][Full Text] [Related]
32. The ultrastructural localization of gross cystic disease fluid protein (GCDFP-15) in breast epithelium.
Mazoujian G; Warhol MJ; Haagensen DE
Am J Pathol; 1984 Aug; 116(2):305-10. PubMed ID: 6205595
[TBL] [Abstract][Full Text] [Related]
33. Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15).
Toth CA; Haagensen DE; Davis S; Zamcheck N; Thomas P
Breast Cancer Res Treat; 1988 Oct; 12(2):235-43. PubMed ID: 3242652
[TBL] [Abstract][Full Text] [Related]
34. Circulating antibodies against the breast tumor marker GCDFP-15/gp17 in mammary carcinoma patients and in patients carrying benign breast conditions.
Pasquinelli R; Barba P; Capasso I; D'Aiuto M; D'Aiuto G; Anzisi AM; De Berardinis P; Guardiola J
Int J Cancer; 1999 Dec; 84(6):568-72. PubMed ID: 10567900
[TBL] [Abstract][Full Text] [Related]
35. Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer.
Bundred NJ; Stewart HJ; Shaw DA; Forrest AP; Miller WR
Eur J Cancer; 1990; 26(11-12):1145-7. PubMed ID: 2149996
[TBL] [Abstract][Full Text] [Related]
36. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast.
Pagani A; Sapino A; Eusebi V; Bergnolo P; Bussolati G
Virchows Arch; 1994; 425(5):459-65. PubMed ID: 7850069
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein.
Ormsby AH; Snow JL; Su WP; Goellner JR
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013
[TBL] [Abstract][Full Text] [Related]
38. Gross cystic disease fluid protein in nipple aspirates of breast fluid of Asian and non-Asian women.
Petrakis NL; Lowenstein JM; Wiencke JK; Lee MM; Wrensch MR; King EB; Hilton JF; Miike R
Cancer Epidemiol Biomarkers Prev; 1993; 2(6):573-9. PubMed ID: 8268776
[TBL] [Abstract][Full Text] [Related]
39. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
Raju U; Ma CK; Shaw A
Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
[TBL] [Abstract][Full Text] [Related]
40. Differential antibody reactivity and CD4 binding of the mammary tumor marker protein GCDFP-15 from breast cyst and its counterparts from exocrine epithelia.
Caputo E; Autiero M; Mani JC; Basmaciogullari S; Piatier-Tonneau D; Guardiola J
Int J Cancer; 1998 Sep; 78(1):76-85. PubMed ID: 9724097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
